Helix BioPharma Appoints Deloitte as Strategic Advisor to Explore Partnering and Licensing Opportunities
Pharmaceutical Investing Helix BioPharma Corp. Announces Licence for Worldwide Right to Anti-CEACAM6 Antibody From the Government of Canada
Helix BioPharma Announces the Signing of a Non-Binding Letter of Intent With ProMab Biotechnologies to Develop Cell Based Therapies
Helix BioPharma Corp. Announces L-DOS47 Immuno-Oncology Scientific Presentation at the Medical University of Warsaw
RUA GOLD Completes the Second Phase of Surface Exploration and Drill Targeting at the Glamorgan Project, New Zealand
Radiopharm Theranostics Accelerates 177Lu-RAD204 Phase 1 Dose Escalation Clinical Trial Based on Positive Recommendation from Data Safety and Monitoring Committee
Finlay Minerals Appoints an Executive Chairman, President & CEO, and Vice President, Corporate Development
